Earnings Call · Q3 FY2022·2022-11-08

Q3 22EPS +45.10%·Rev n/aQ2 22EPS +6.00%·Rev n/aQ1 22EPS -4.08%·Rev n/aQ4 21EPS +2.44%·Rev n/a⚠ consensus missing

HALOZYME THERAPEUTICS, INC. HALO

Tram Bui — Investor Relations

Helen Torley — Chief Executive Officer

Nicole LaBrosse — Chief Financial Officer

+8.5%1d on move date+10.5% vs SPY3d+17.8%5d+17.9%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more HALO calls or request research access.

More HALO calls Browse calls Request research access